RUMORED BUZZ ON LINSITINIB CLINICAL TRIALS

The LIDS trial fulfilled its Most important endpoint with statistical importance for your 150mg BID dose. Linsitinib On this trial validated the protection profile found within the prior oncology reports and importantly shown a good protection profile on key adverse activities (AEs) of curiosity to the IGF-1R focus on such as Listening to impairmen